Further mechanical experiments identified the SMAD4 can regulate ASCL1 transcription competitively with Myc in NSCLC cells and Myc inhibitor acts as a potential subsequent treatment agent. This evidence concerns the gene SMAD4 and non-small cell lung carcinoma.